68Ga-FAP-2286 for Pulmonary Fibrosis

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Pulmonary Fibrosis+2 More68Ga-FAP-2286 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will help researchers learn if FAP-2286 can be used to help identify different types of fibrosis and if it is safe for human use.

Eligible Conditions
  • Pulmonary Fibrosis
  • Liver Fibrosis
  • Myocardial Fibrosis

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

4 Primary · 0 Secondary · Reporting Duration: Up to 31 days

Up to 1 days
Median peak standardized uptake value (SUV) in myocardium region
Liver
Lung
Up to 31 days
Proportion of participants with treatment-related adverse events

Trial Safety

Safety Progress

1 of 3

Trial Design

3 Treatment Groups

Cohort 1: Liver Fibrosis
1 of 3
Cohort 2: Pulmonary Fibrosis
1 of 3
Cohort 3: Myocardial Fibrosis
1 of 3

Experimental Treatment

30 Total Participants · 3 Treatment Groups

Primary Treatment: 68Ga-FAP-2286 · No Placebo Group · Phase 1

Cohort 1: Liver FibrosisExperimental Group · 2 Interventions: 68Ga-FAP-2286, Positron Emission Tomography (PET) · Intervention Types: Drug, Procedure
Cohort 2: Pulmonary FibrosisExperimental Group · 2 Interventions: 68Ga-FAP-2286, Positron Emission Tomography (PET) · Intervention Types: Drug, Procedure
Cohort 3: Myocardial FibrosisExperimental Group · 2 Interventions: 68Ga-FAP-2286, Positron Emission Tomography (PET) · Intervention Types: Drug, Procedure
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Positron Emission Tomography (PET)
2019
Completed Phase 4
~1320

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 31 days

Who is running the clinical trial?

Clovis Oncology, Inc.Industry Sponsor
62 Previous Clinical Trials
10,301 Total Patients Enrolled
Thomas HopeLead Sponsor
8 Previous Clinical Trials
1,589 Total Patients Enrolled
Thomas A Hope, MDPrincipal InvestigatorUniversity of California, San Francisco
2 Previous Clinical Trials
499 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 6 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Cohort 2: Pulmonary fibrosis, based on CT findings or biopsy of lung parenchyma.
You are able to understand and sign a written informed consent document.